Dr. Madhavi Chada, M. D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 12150 Annapolis Rd Ste 209, Glenn Dale, MD 20769 Phone: 240-929-6652 Fax: 240-929-6710 |
News Archive
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.
Muscular dystrophy, which affects approximately 250,000 people in the U.S., occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function. For years, scientists have searched for a way to successfully treat the most common form of the disease, Duchenne Muscular Dystrophy (DMD), which primarily affects boys. Now, a team of University of Missouri researchers have successfully treated dogs with DMD and say that human clinical trials are being planned in the next few years.
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
Neutra Corp. (OTCBB: NTRR), a growing provider of all-natural wellness solutions, is proud to announce that its partner, Purlife, has signed a deal with one of Canada's largest automotive warranty companies to make its revolutionary Drivepur Protection System available to a network of 1,200 car dealerships.
A team of researchers from various institutions within the Netherlands examined the use of targeted MS-based proteomics for the detection of SARS-CoV-2 in research and clinical samples.
› Verified 7 days ago